Moreover, lithium concentrations suitable for treating psychiatric disorders are often too low to contrast other GSK‐3β‐dependent illnesses, such as neurodegenerative diseases or viral infections.[56] Therefore, organ‐specific lithium‐releasing devices that ensure an efficient release of the cation and overcome the side effects due to high‐concentration therapeutic doses would be highly desirable. The gene discussed is GSK3B; the disease is psychiatric disorder.